200 related articles for article (PubMed ID: 21689131)
1. Efficacy and safety of the 2% formulation of testosterone topical solution applied to the axillae in androgen-deficient men.
Wang C; Ilani N; Arver S; McLachlan RI; Soulis T; Watkinson A
Clin Endocrinol (Oxf); 2011 Dec; 75(6):836-43. PubMed ID: 21689131
[TBL] [Abstract][Full Text] [Related]
2. Skin reactions in a phase 3 study of a testosterone topical solution applied to the axilla in hypogonadal men.
Muram D; Melby T; Alles Kingshill E
Curr Med Res Opin; 2012 May; 28(5):761-6. PubMed ID: 22458919
[TBL] [Abstract][Full Text] [Related]
3. Testosterone replacement therapy does not promote priapism in hypogonadal men with sickle cell disease: 12-month safety report.
Morrison BF; Reid M; Madden W; Burnett AL
Andrology; 2013 Jul; 1(4):576-82. PubMed ID: 23606509
[TBL] [Abstract][Full Text] [Related]
4. [Scrotal testosterone patches: a good addition to therapeutic options for hypogonadal men].
Asscheman H; Gooren LJ
Ned Tijdschr Geneeskd; 2000 Apr; 144(18):847-50. PubMed ID: 10816775
[TBL] [Abstract][Full Text] [Related]
5. The long-term efficacy and safety of a testosterone mucoadhesive buccal tablet in testosterone-deficient men.
Dinsmore WW; Wyllie MG
BJU Int; 2012 Jul; 110(2):162-9. PubMed ID: 22288877
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
Coward RM; Simhan J; Carson CC
BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
[TBL] [Abstract][Full Text] [Related]
7. Utility of a single serum testosterone measurement to determine response to topical testosterone replacement in hypogonadal men.
Muram D; Ni X
Curr Med Res Opin; 2016; 32(2):263-9. PubMed ID: 26549704
[TBL] [Abstract][Full Text] [Related]
8. One-year efficacy and safety study of a 1.62% testosterone gel in hypogonadal men: results of a 182-day open-label extension of a 6-month double-blind study.
Kaufman JM; Miller MG; Fitzpatrick S; McWhirter C; Brennan JJ
J Sex Med; 2012 Apr; 9(4):1149-61. PubMed ID: 22321357
[TBL] [Abstract][Full Text] [Related]
9. Testosterone therapy in men with Parkinson disease: results of the TEST-PD Study.
Okun MS; Fernandez HH; Rodriguez RL; Romrell J; Suelter M; Munson S; Louis ED; Mulligan T; Foster PS; Shenal BV; Armaghani SJ; Jacobson C; Wu S; Crucian G
Arch Neurol; 2006 May; 63(5):729-35. PubMed ID: 16682542
[TBL] [Abstract][Full Text] [Related]
10. A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function.
McNicholas TA; Dean JD; Mulder H; Carnegie C; Jones NA
BJU Int; 2003 Jan; 91(1):69-74. PubMed ID: 12614254
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of changing testosterone gel preparations (Androgel or Testim) among suboptimally responsive hypogonadal men.
Grober ED; Khera M; Soni SD; Espinoza MG; Lipshultz LI
Int J Impot Res; 2008; 20(2):213-7. PubMed ID: 17898800
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a General Clinical Research Center Study.
Wang C; Berman N; Longstreth JA; Chuapoco B; Hull L; Steiner B; Faulkner S; Dudley RE; Swerdloff RS
J Clin Endocrinol Metab; 2000 Mar; 85(3):964-9. PubMed ID: 10720024
[TBL] [Abstract][Full Text] [Related]
13. Transdermal testosterone gel: pharmacokinetics, efficacy of dosing and application site in hypogonadal men.
Meikle AW; Matthias D; Hoffman AR
BJU Int; 2004 Apr; 93(6):789-95. PubMed ID: 15049991
[TBL] [Abstract][Full Text] [Related]
14. Double-blind placebo-controlled study of testosterone patch therapy on bone turnover in men with borderline hypogonadism.
Merza Z; Blumsohn A; Mah PM; Meads DM; McKenna SP; Wylie K; Eastell R; Wu F; Ross RJ
Int J Androl; 2006 Jun; 29(3):381-91. PubMed ID: 16390499
[TBL] [Abstract][Full Text] [Related]
15. A small-scale clinical trial to determine the safety and efficacy of testosterone replacement therapy in hypogonadal men with spinal cord injury.
Bauman WA; Cirnigliaro CM; La Fountaine MF; Jensen AM; Wecht JM; Kirshblum SC; Spungen AM
Horm Metab Res; 2011 Jul; 43(8):574-9. PubMed ID: 21717386
[TBL] [Abstract][Full Text] [Related]
16. Open-label pilot study of testosterone patch therapy in men with opioid-induced androgen deficiency.
Daniell HW; Lentz R; Mazer NA
J Pain; 2006 Mar; 7(3):200-10. PubMed ID: 16516826
[TBL] [Abstract][Full Text] [Related]
17. Testosterone replacement therapy improves mood in hypogonadal men--a clinical research center study.
Wang C; Alexander G; Berman N; Salehian B; Davidson T; McDonald V; Steiner B; Hull L; Callegari C; Swerdloff RS
J Clin Endocrinol Metab; 1996 Oct; 81(10):3578-83. PubMed ID: 8855804
[TBL] [Abstract][Full Text] [Related]
18. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men.
Zhang GY; Gu YQ; Wang XH; Cui YG; Bremner WJ
J Androl; 1998; 19(6):761-8. PubMed ID: 9876028
[TBL] [Abstract][Full Text] [Related]
19. Transdermal testosterone gel increases serum testosterone levels in hypogonadal men in Taiwan with improvements in sexual function.
Chiang HS; Hwang TI; Hsui YS; Lin YC; Chen HE; Chen GC; Liao CH
Int J Impot Res; 2007; 19(4):411-7. PubMed ID: 17538639
[TBL] [Abstract][Full Text] [Related]
20. Testosterone supplementation: what and how to give.
Jockenhövel F
Aging Male; 2003 Sep; 6(3):200-6. PubMed ID: 14628500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
